Abstract
To investigate the effect of early treatment with hepatocyte growth factor (HGF) on the cytokine expression and pulmonary artery, right ventricular (RV) remodeling in the rat model of pulmonary artery hypertension (PAH). The rat model of PAH was produced by injecting monocrotaline, and the model rats were randomly divided into empty adenovirus transfection group (MCT group, n = 10) and HGF gene transfection group(HGF group, n = 10). Another group of rats served as the Sham operation group (Sham group n = 10). After 4 weeks of HGF gene transfection, the histological sections of the lungs and right ventricular (RV) were stained with hematoxylin-eosin (HE) and the pulmonary artery and RV remodeling were examined. The rat lung sections were also immunostained with antibodies against factor VIII, and the capillary density were calculated. Meanwhile, the mRNA expression of TNF-α, IL-6, IL-1β and TGF-β1 in pulmonary arteries and RV were detected by RT-PCR. HGF gene treatment significantly decreased the ratio of vessel wall thickness to pulmonary artery diameter and the ratio of vessel wall area to total area, and increased the capillary density of lung in PAH rats. HGF gene treatment also significantly decreased cross-sectional area of cardiomyocytes and collagen deposited in RV. Moreover, HGF gene treatment significantly decreased the expression of cytokines in pulmonary artery (TNF-α: 0.82 ± 0.07 vs 0.49 ± 0.09, IL-6: 1.13 ± 0.19 vs 0.68 ± 0.09, IL-1β: 0.86 ± 0.11 vs 0.51 ± 0.07, TGF-β1: 1.18 ± 0.12 vs 0.59 ± 0.10) and RV (TNF-α: 0.79 ± 0.11 vs 0.48 ± 0.08, IL-6: 1.03 ± 0.11 vs 0.63 ± 0.09, IL-1β: 0.81 ± 0.11 vs 0.52 ± 0.07, TGF-β1: 0.94 ± 0.12 vs 0.53 ± 0.10) in MCT induced PAH rats (P < 0.05) . Early treatment with HGF improves pulmonary artery and RV remodeling, possibly by decreasing the expression of TNF-α, IL-6, IL-1β and TGF-β1 in pulmonary arteries and RV.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Tuberculosis and Respiratory Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
